Policy Name
|
Category
|
|---|
| Acne Agents, Oral |
Statewide PDL Prior Authorization Criteria Policy |
| Acne Agents, Topical |
Statewide PDL Prior Authorization Criteria Policy |
| Alcohol Use Disorder Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Alpha-1 Proteinase Inhibitors |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Alzheimer's Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Alzheimer's Antiamyloid Monoclonal Antibodies |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Amyotrophic lateral sclerosis (ALS) Medications |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Analgesics, Non-Opioid Barbituate Combinations |
Statewide PDL Prior Authorization Criteria Policy |
| Analgesics, Opioid Long-Acting |
Statewide PDL Prior Authorization Criteria policy |
| Analgesics, Opioid Short-Acting |
Statewide PDL Prior Authorization Criteria Policy |
| Androgenic Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Angiotensin Modulator Combinations |
Statewide PDL Prior Authorization Criteria Policy |
| Angiotensin Modulators |
Statewide PDL Prior Authorization Criteria Policy |
| Antianginal Agent |
Statewide PDL Prior Authorization Criteria Policy |
| Antibiotics, GI and related |
Statewide PDL Prior Authorization Criteria Policy |
| Antibiotics, Inhaled |
Statewide PDL Prior Authorization Criteria policy |
| Antibiotics, Topical |
Statewide PDL Prior Authorization Criteria policy |
| Anticoagulants |
Statewide PDL Prior Authorization Criteria Policy |
| Anticonvulsants |
Statewide PDL Prior Authorization Criteria Policy |
| Antidepressants, Other |
Statewide PDL Prior Authorization Criteria Policy |
| Antidepressants, SSRI |
Statewide PDL Prior Authorization Criteria Policy |
| Antiemetic-Antivertigo Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Antifibrotic Respiratory Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Antifungals, Oral |
Statewide PDL Prior Authorization Criteria Policy |
| Antifungals, Topical |
Statewide PDL Prior Authorization Criteria Policy |
| Antihemophilia Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Antihistamines, Minimally Sedating |
Statewide PDL Prior Authorization Criteria policy |
| Antihypertensives, Sympatholytic |
Statewide PDL Prior Authorization Criteria Policy |
| Antihyperuricemics |
Statewide PDL Prior Authorization Criteria Policy |
| Antimalarials |
Statewide PDL Prior Authorization Criteria Policy |
| Antiparasitics, Topical |
Statewide PDL Prior Authorization Criteria Policy |
| Antiparkinson's Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Antipsoriatics, Oral |
Statewide PDL Prior Authorization Criteria Policy |
| Antipsoriatics, Topical |
Statewide PDL Prior Authorization Criteria Policy |
| Antipsychotics |
Statewide PDL Prior Authorization Criteria Policy |
| Antivirals, CMV |
Statewide PDL Prior Authorization Criteria Policy |
| Antivirals, Herpes |
Statewide PDL Prior Authorization Criteria Policy |
| Antivirals, Influenza |
Statewide PDL Prior Authorization Criteria Policy |
| Anxiolytics |
Statewide PDL Prior Authorization Criteria Policy |
| Beta Blockers |
Statewide PDL Prior Authorization Criteria Policy |
| Bile Salts |
Statewide PDL Prior Authorization Criteria Policy |
| Bladder Relaxant Preparations |
Statewide PDL Prior Authorization Criteria Policy |
| Blood Glucose Meters and Test Strips |
Statewide PDL Prior Authorization Criteria Policy |
| Bone Density Regulators |
Statewide PDL Prior Authorization Criteria Policy |
| Botulinum Toxins |
Statewide PDL Prior Authorization Criteria Policy |
| BPH Treatments |
Statewide PDL Prior Authorization Criteria Policy |
| Brineura |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Bronchodilators, Beta Agonists |
Statewide PDL Prior Authorization Criteria Policy |
| Bylvay |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| C5b and C3 Complement Inhibitors |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Calcium Channel Blockers |
Statewide PDL Prior Authorization Criteria Policy |
| Casgevy |
Statewide PDL Prior Authorization Criteria Policy |
| Cephalosporins |
Statewide PDL Prior Authorization Criteria Policy |
| Chimeric Antigen Receptor T-cell (CAR-T) Immunotherapy |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Colony Stimulating Factors |
Statewide PDL Prior Authorization Criteria Policy |
| Complement Inhibitors |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Compounds |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Continuous Glucose Monitoring Products |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Contraceptives, Oral |
Statewide PDL Prior Authorization Criteria Policy |
| Contraceptives, Other |
Statewide PDL Prior Authorization Criteria Policy |
| COPD Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Corticotropin (H.P. Acthar, Purified Cortrophin Gel) |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Cough and Cold Medications for Children less than 4 |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Crysvita |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Cystic Fibrosis Biologic Response Modifiers |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Cytokine and CAM Antagonists |
Statewide PDL Prior Authorization Criteria Policy |
| Daraprim |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Daybue (trofinetide) |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Dry Eye Treatments |
Statewide PDL Prior Authorization Criteria Policy |
| Duchenne Muscular Dystrophy (DMD) Antisense Oligonucleotides |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Dupixent |
Statewide PDL Prior Authorization Criteria Policy |
| Duvyzat (givinostat) |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Enspryng (satralizumab-mwge) and Uplizna (inebilizumab-cdon) |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Enzyme Replacement Therapy, Pompe Disease |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Enzyme Replacements, Gaucher Disease |
Statewide PDL Prior Authorization Criteria Policy |
| Epinephrine, Self-Injected |
Statewide PDL Prior Authorization Criteria Policy |
| Erythropoiesis Stimulating Proteins |
Statewide PDL Prior Authorization Criteria Policy |
| Estrogens |
Statewide PDL Prior Authorization Criteria Policy |
| Fabry Disease Medications |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Filspari |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Firdapse |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Fluoroquinolones, Oral |
Statewide PDL Prior Authorization Criteria Policy |
| Gamifant |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Gattex |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Gene Therapy Agents |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| GI Motility, Chronic |
Statewide PDL Prior Authorization Criteria Policy |
| Givlaari |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Glucocorticoids, Inhaled |
Statewide PDL Prior Authorization Criteria Policy |
| Glucocorticoids, Oral |
Statewide PDL Prior Authorization Criteria Policy |
| Growth Hormones |
Statewide PDL Prior Authorization Criteria Policy |
| H. Pylori Treatments |
Statewide PDL Prior Authorization Criteria Policy |
| Hematopoietic Mixtures |
Statewide PDL Prior Authorization Criteria Policy |
| Hepatitis B Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Hepatitis C Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Hereditary Angioedema Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Histamine 2 Receptor Blockers |
Statewide PDL Prior Authorization Criteria Policy |
| HIV/AIDS Antiretrovirals |
Statewide PDL Prior Authorization Criteria Policy |
| Hypoglycemia Treatments |
Statewide PDL Prior Authorization Criteria Policy |
| Hypoglycemics, Alpha-Glucosidase Inhibitors |
Statewide PDL Prior Authorization Criteria Policy |
| Hypoglycemics, Incretin Mimetics/Enhancers |
Statewide PDL Prior Authorization Criteria Policy |
| Hypoglycemics, Insulin and Related Agent |
Statewide PDL Prior Authorization Criteria Policy |
| Hypoglycemics, Meglitinides |
Statewide PDL Prior Authorization Criteria Policy |
| Hypoglycemics, Metformins |
Statewide PDL Prior Authorization Criteria Policy |
| Hypoglycemics, SGLT2 Inhibitors |
Statewide PDL Prior Authorization Criteria Policy |
| Hypoglycemics, Sulfonylureas |
Statewide PDL Prior Authorization Criteria Policy |
| Hypoglycemics, TZDs |
Statewide PDL Prior Authorization Criteria Policy |
| Imcivree (setmelanotide) |
|
| Immune Globulin Products |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Immunomodulators, Atopic Dermatitis |
Statewide PDL Prior Authorization Criteria Policy |
| Immunomodulators, Topical |
Statewide PDL Prior Authorization Criteria Policy |
| Immunosuppressives, Oral |
Statewide PDL Prior Authorization Criteria Policy |
| Intra-Articular Hyaluronates |
Statewide PDL Prior Authorization Criteria Policy |
| Intranasal Rhinitis Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Iron Chelating Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Iron, Parenteral |
Statewide PDL Prior Authorization Criteria Policy |
| Isturisa |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Joenja |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Journavx (Suzetrigine) |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Lantidra |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Leukotriene Modifiers |
Statewide PDL Prior Authorization Criteria Policy |
| Lipotropics, Other |
Statewide PDL Prior Authorization Criteria Policy |
| Lipotropics, Statins |
Statewide PDL Prior Authorization Criteria Policy |
| Livmarli |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Local Anesthetics, Topical |
Statewide PDL Prior Authorization Criteria Policy |
| Luxturna |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Lyfgenia |
Statewide PDL Prior Authorization Criteria Policy |
| Macrolides |
Statewide PDL Prior Authorization Criteria Policy |
| Macular Degeneration Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Methotrexate |
Statewide PDL Prior Authorization Criteria Policy |
| Migraine Acute Treatment Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Migraine Prevention Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Monoclonal Antibodies (MABs)- Anti-IL, Anti-IgE, Anti-TSLP |
Statewide PDL Prior Authorization Criteria Policy |
| Multiple Sclerosis Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Myalept |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Myasthenia Gravis Medications |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Natalizumab |
Statewide PDL Prior Authorization Criteria Policy |
| Neuropathic Pain Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Non-Formulary Medical Necessity |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| NSAIDS |
Statewide PDL Prior Authorization Criteria Policy |
| Nuedexta |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Obesity Treatment Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Oncology Agents, Breast Cancer |
Statewide PDL Prior Authorization Criteria Policy |
| Oncology Agents, Oral |
Statewide PDL Prior Authorization Criteria Policy |
| Oncology, IV/Injectable |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Onpattro,Tegsedi and Amvuttra |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Ophthalmics, Allergic Conjunctivitis |
Statewide PDL Prior Authorization Criteria Policy |
| Ophthalmics, Antibiotics |
Statewide PDL Prior Authorization Criteria Policy |
| Ophthalmics, Antibiotic-Steroid Combinations |
Statewide PDL Prior Authorization Criteria Policy |
| Ophthalmics, Anti-inflammatories |
Statewide PDL Prior Authorization Criteria Policy |
| Ophthalmics, Glaucoma |
Statewide PDL Prior Authorization Criteria Policy |
| Opioid Overdose Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Opioid Use Disorder Treatments |
Statewide PDL Prior Authorization Criteria Policy |
| Otic Antibiotics |
Statewide PDL Prior Authorization Criteria Policy |
| Palforzia |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Pancreatic Enzymes |
Statewide PDL Prior Authorization Criteria Policy |
| Penicillins |
Statewide PDL Prior Authorization Criteria Policy |
| Phenylketonuria Medications |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Phosphate Binders |
Statewide PDL Prior Authorization Criteria Policy |
| Pituitary Suppressive Agents, LHRH |
Statewide PDL Prior Authorization Criteria Policy |
| Platelet Aggregation Inhibitors |
Statewide PDL Prior Authorization Criteria Policy |
| Potassium Removing Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Prenatal Vitamins |
Statewide PDL Prior Authorization Criteria Policy |
| Progestational Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Proton Pump Inhibitors |
Statewide PDL Prior Authorization Criteria policy |
| Pulmonary Arterial Hypertension (PAH) Agents, Injectable |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Pulmonary Arterial Hypertension (PAH) Agents, Oral and Inhaled |
Statewide PDL Prior Authorization Criteria Policy |
| Pulmozyme |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Qbrexza |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Quantity Limits |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Rezdiffra (resmetirom) |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Rituxan |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Sandostatin LAR Depot |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Sedative Hypnotics |
Statewide PDL Prior Authorization Criteria |
| Selective Transthyretin (TTR) Stabilizers |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Sickle Cell Anemia Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Skeletal Muscle Relaxants |
Statewide PDL Prior Authorization Criteria Policy |
| Skyclarys |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Smoking Cessation |
Statewide PDL Prior Authorization Criteria Policy |
| Sohonos |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Somatuline Depot |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Spinal Muscular Atrophy Medications |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Steroids, Topical |
Statewide PDL Prior Authorization Criteria Policy |
| Stimulants and Related Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Strensiq |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Sublingual Immunotherapy Medications |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Sucraid |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| |
|
| Systemic Lupus Erythematosus (SLE) Agents |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Tepezza |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Tetracyclines |
Statewide PDL Prior Authorization Criteria Policy |
| Thalidomide and Derivatives |
Statewide PDL Prior Authorization Criteria Policy |
| Thrombopoietics |
Statewide PDL Prior Authorization Criteria Policy |
| Thyroid Hormones |
Statewide PDL Prior Authorization Criteria Policy |
| Tubeless Insulin Delivery Devices |
Statewide PDL Prior Authorization Criteria Policy |
| Tzield |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Ulcerative Colitis Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Uplizna |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Urea Cycle Disorder Agents |
Statewide PDL Prior Authorization Criteria Policy |
| Urinary Anti-Infectives |
Statewide PDL Prior Authorization Criteria Policy |
| Vaginal Anti-Infectives |
Statewide PDL Prior Authorization Criteria Policy |
| Vitamin D Analogs |
Statewide PDL Prior Authorization Criteria Policy |
| VMAT2 Inhibitors |
Statewide PDL Prior Authorization Criteria Policy |
| Vyjuvek |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Xenpozyme |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Xiaflex |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Xyrem, Xywav, and Lumryz |
Highmark Wholecare Non-PDL Prior Authorization Criteria |
| Zeposia |
Statewide PDL Prior Authorization Criteria Policy |
| Zynteglo |
|